Inflammatory Myositis (IM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Inflammatory Myositis (IM) Market Outlook

Thelansis’s “Inflammatory Myositis (IM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inflammatory Myositis (IM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Inflammatory Myositis (IM) Overview

Inflammatory myopathies represent a spectrum of muscular disorders characterized by inflammation, stemming from autoimmune dysregulation wherein the body’s immune system erroneously targets its own muscle tissues. Predominant among these conditions are dermatomyositis and polymyositis, though the taxonomy of inflammatory myopathies remains dynamic, with ongoing identification of novel subtypes. Dermatomyositis primarily manifests as muscle weakness, notably affecting the musculature of the cervical, scapular, and pelvic regions, and also presents with cutaneous manifestations. Respiratory compromise may also ensue in some instances. While inflammatory myopathies can affect individuals across age groups and ethnicities, their incidence is relatively infrequent, with a predilection for onset in childhood (typically between ages 5 and 10) and adulthood (typically between ages 40 and 50) and a higher occurrence in females compared to males.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Inflammatory Myositis (IM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034